Symbols

PHAR

Pharming Group·NASDAQ

--(--)

PHAR fundamentals

PHAR Q4 2025 Earnings

Pharming Group (PHAR) released its earnings on Mar 12, 2026: revenue was 106.50M (YoY +14.89%), missed estimates; EPS was 0.07 (YoY +40.00%), beat estimates.

Revenue / YoY

106.50M

+14.89%

EPS / YoY

0.07

+40.00%

Report date

Mar 12, 2026

PHAR Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue $106.5M (+15% YoY), full-year $376.1M (+27% YoY). 2026 guidance: $405-425M (+8-13%).
Profitability: Operating profit $26M (vs. loss in 2024). Operating cash flow $54.7M.
Pipeline Momentum: Leniolisib Phase II trials (PIDs) and napazimone pivotal study (mitochondrial disease) advancing.
Joenja Expansion: 70-75% of 2026 growth from U.S., international launches in 2026. FDA Type A meeting scheduled for March 2026.
RUCONEST Resilience: 26% YoY growth, 60 new U.S. enrollments Q4. Q1 2026 U.S. revenue growth -7% to -9% due to inventory drawdown.

Earnings

EPS

Revenue

Revenue & Expenses

PHAR has released its 2025 Q4 earnings report, with revenue of 106.53M, reflecting a YoY change of 14.96%, and net profit of 5.33M, showing a YoY change of 86.36%. The Sankey diagram below clearly presents PHAR's revenue sources and cost distribution.

Key Indicators

Pharming Group (PHAR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Pharming Group (PHAR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Pharming Group (PHAR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Pharming Group (PHAR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown